Reduced-antigen, combined diphtheria, tetanus and three-component acellular pertussis
vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus …

Objectives Actively recruit and intensively follow pregnant women receiving a dose of
acellular pertussis vaccine for 4 weeks after vaccination. Design and settings A prospective …

Extensive use of meningococcal AC polysaccharide (MACP) vaccines has raised concerns
about induction of immunologic hyporesponsiveness to C polysaccharide. We investigated …

Reduced-antigen, combined diphtheria, tetanus, and acellular pertactin-containing pertussis
vaccine (dTpa; Boostrix™) contains reduced quantities of the same toxoids/antigens found …

Pertussis remains a serious problem in many countries. Even in countries with high vaccine
coverage and a long vaccination history, pertussis outbreaks occur periodically. Rather than …

Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis
vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus …

Reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, Boostrix™,
is indicated for booster vaccination of children, adolescents and adults. The original prefilled …

Despite effective infant immunization against pertussis, the disease continues to circulate
due to waning immunity. Booster vaccinations against pertussis beyond infancy are widely …

MATERIALS AND METHODS Study design. This was a single-group (divided upon analysis
by vaccination history—naïve or previously vaccinated), open-label phase IV study. Subjects …